Literature DB >> 33670901

Data Integration Reveals the Potential Biomarkers of Circulating MicroRNAs in Osteoarthritis.

Thuan Duc Lao1, Thuy Ai Huyen Le1.   

Abstract

The abnormal expression of circulating miRNAs (c-miRNAs) has become an emerging field in the development of miRNAs-based diagnostic and therapeutic tools for human diseases, including osteoarthritis (OA). OA is the most common form of arthritis leading to disability and a major socioeconomic burden. The abnormal expression of miRNAs plays important roles in the pathogenesis of OA. Unraveling the role of miRNAs in the pathogenesis of OA will throw light on the potential for the development of miRNAs-based diagnostic and therapeutic tools for OA. This article reviews and highlights recent advances in the study of miRNAs in OA, with specific demonstration of the functions of miRNA, especially c-miRNA, in OA pathogenesis as well as its potential implication in the treatment of OA. Based on a systematic literature search using online databases, we figured out the following main points: (1) the integrative systematic review of c-mRNAs and its target genes related to OA pathogenesis; (2) the potential use of c-miRNAs for OA diagnosis purposes as potential biomarkers; and (3) for therapeutic purposes, and we also highlight certain remedies that regulate microRNA expression based on its target genes.

Entities:  

Keywords:  circulating miRNAs; miRNAs-based diagnosis; miRNAs-based therapeutic; osteoarthritis

Year:  2021        PMID: 33670901      PMCID: PMC7997238          DOI: 10.3390/diagnostics11030412

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  93 in total

1.  Elevated expression of microRNA-30b in osteoarthritis and its role in ERG regulation of chondrocyte.

Authors:  Lisong Li; Cao Yang; Xianzhe Liu; Shuhua Yang; Shunan Ye; Jie Jia; Wei Liu; Yukun Zhang
Journal:  Biomed Pharmacother       Date:  2015-11-12       Impact factor: 6.529

Review 2.  Occupational risk factors for osteoarthritis of the knee: a meta-analysis.

Authors:  D F McWilliams; B F Leeb; S G Muthuri; M Doherty; W Zhang
Journal:  Osteoarthritis Cartilage       Date:  2011-03-05       Impact factor: 6.576

Review 3.  Recent advances in biomarkers in osteoarthritis.

Authors:  Debabrata Patra; Linda J Sandell
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

4.  miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis.

Authors:  Ahu Soyocak; Hulyam Kurt; Merih Ozgen; Didem Turgut Cosan; Ertugrul Colak; Hasan Veysi Gunes
Journal:  Gene       Date:  2017-06-21       Impact factor: 3.688

5.  Utility of circulating serum miRNAs as biomarkers of early cartilage degeneration in animal models of post-traumatic osteoarthritis and inflammatory arthritis.

Authors:  L H W Kung; S Zaki; V Ravi; L Rowley; M M Smith; K M Bell; J F Bateman; C B Little
Journal:  Osteoarthritis Cartilage       Date:  2016-09-09       Impact factor: 6.576

6.  MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses.

Authors:  Shigeru Miyaki; Tomoyuki Nakasa; Shuhei Otsuki; Shawn P Grogan; Reiji Higashiyama; Atsushi Inoue; Yoshio Kato; Tempei Sato; Martin K Lotz; Hiroshi Asahara
Journal:  Arthritis Rheum       Date:  2009-09

7.  Relationship of miRNA-146a to primary Sjögren's syndrome and to systemic lupus erythematosus: a meta-analysis.

Authors:  Hong-Yan Sun; An-Kun Lv; Hua Yao
Journal:  Rheumatol Int       Date:  2017-06-01       Impact factor: 2.631

8.  MicroRNA-23a-3p promotes the development of osteoarthritis by directly targeting SMAD3 in chondrocytes.

Authors:  Liang Kang; Cao Yang; Yu Song; Wei Liu; Kun Wang; Shuai Li; Yukun Zhang
Journal:  Biochem Biophys Res Commun       Date:  2016-06-16       Impact factor: 3.575

9.  miR-122/SIRT1 axis regulates chondrocyte extracellular matrix degradation in osteoarthritis.

Authors:  Yinwei Bai; Kun Chen; Jianfeng Zhan; Mingxin Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.